Biotechnology Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies – BioXcel Therapeutics (NASDAQ:BTAI), Bristol-Myers Squibb (NYSE:BMY) Read more
Biotechnology Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline – Valneva (NASDAQ:VALN) Read more
Biotechnology ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI) Read more
Biotechnology Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU Read more